Poly(ADP-ribose) polymerase 9 mediates early protection against Mycobacterium tuberculosis infection by regulating type I IFN production
Journal of Clinical Investigation · 2023
DOI: 10.1172/jci158630 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2023. Verfasst von Shyamala Thirunavukkarasu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Microbiology. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, NIH HHS.
Abstract (Originalsprache)
The ADP ribosyltransferases (PARPs 1-17) regulate diverse cellular processes, including DNA damage repair. PARPs are classified on the basis of their ability to catalyze poly-ADP-ribosylation (PARylation) or mono-ADP-ribosylation (MARylation). Although PARP9 mRNA expression is significantly increased in progressive tuberculosis (TB) in humans, its participation in host immunity to TB is unknown. Here, we show that PARP9 mRNA encoding the MARylating PARP9 enzyme was upregulated during TB in humans and mice and provide evidence of a critical modulatory role for PARP9 in DNA damage, cyclic GMP-AMP synthase (cGAS) expression, and type I IFN production during TB. Thus, Parp9-deficient mice were susceptible to Mycobacterium tuberculosis infection and exhibited increased TB disease, cGAS and 2'3'-cyclic GMP-AMP (cGAMP) expression, and type I IFN production, along with upregulation of complement and coagulation pathways. Enhanced M. tuberculosis susceptibility is type I IFN dependent, as blockade of IFN α receptor (IFNAR) signaling reversed the enhanced susceptibility of Parp9-/- mice. Thus, in sharp contrast to PARP9 enhancement of type I IFN production in viral infections, this member of the MAR family plays a protective role by limiting type I IFN responses during TB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Microbiology.
- McDonnell Genome Institute, and.
- Division of Infectious Diseases, Department of Internal Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Medicine, Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA.
- South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Förderung
- NIAID NIH HHS
- NHLBI NIH HHS
- NIH HHS
- NIH
Zitieren
APA
Thirunavukkarasu, S., Ahmed, M., Rosa, B. A., Boothby, M., Cho, S. H., Rangel-Moreno, J., Mbandi, S. K., Schreiber, V., Gupta, A., Zuniga, J., Mitreva, M., Kaushal, D., Scriba, T. J., & Khader, S. A. (2023). Poly(ADP-ribose) polymerase 9 mediates early protection against Mycobacterium tuberculosis infection by regulating type I IFN production. Journal of Clinical Investigation. https://doi.org/10.1172/jci158630
Vancouver
Thirunavukkarasu S, Ahmed M, Rosa BA, Boothby M, Cho SH, Rangel-Moreno J, et al. Poly(ADP-ribose) polymerase 9 mediates early protection against Mycobacterium tuberculosis infection by regulating type I IFN production. Journal of Clinical Investigation. 2023. doi:10.1172/jci158630
BibTeX
@article{Thirunavukkarasu2023,
author = {Thirunavukkarasu, Shyamala and Ahmed, Mushtaq and Rosa, Bruce A and Boothby, Mark and Cho, Sung Hoon and Rangel-Moreno, Javier and Mbandi, Stanley K and Schreiber, Valérie and Gupta, Ananya and Zuniga, Joaquin and Mitreva, Makedonka and Kaushal, Deepak and Scriba, Thomas J and Khader, Shabaana A},
title = {Poly(ADP-ribose) polymerase 9 mediates early protection against Mycobacterium tuberculosis infection by regulating type I IFN production},
journal = {Journal of Clinical Investigation},
year = {2023},
doi = {10.1172/jci158630}
}
EUVIMED